NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
02/02/2026
Back to search
Official data from USPTO
AFFILIN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
AFFILIN
ST13
US500000079155885Class
1, 5, 42
Filing
79155885
Registration
4838850
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
45
Latest update
02/03/2026
Classification
Registered
Trademark type
Word
Nice classes
1, 5, 42
Filing date
07/29/2014
Registration date
10/27/2015
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/02/2026
Last transaction
02/03/2026
Responsible office
United States Patent and Trademark Office
Status code
706
Official register
Principal Register
Drawing code
4
Owner type
27
Owner location
Halle, DE
Examiner
HUSSAIN, TASNEEM
Current location
Historical data usage
Holders and representatives
Holders
Scil Proteins GmbH
Scil Proteins GmbH
Representatives
Miki Motohashi Iino Millen, White, Zelano & Branigan, P.C.
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals used in industry and sciencein particular comprising antibody-like proteins or artificial proteinsexcept finishing agents for the preparation of synthetic and natural fibres; polypeptides and proteins for industrial purposesincluding the manufacturing and purification of proteinspolypeptideschemicals and other substances; diagnostic and analytic preparations for scientific or research usenot for medical or veterinary use; chemical reagents for analysis in laboratoriesnot for medical or veterinary use; biological tissue cultures for laboratoriesnot for medical or veterinary use; biological tissue cultures for laboratory analysis and diagnostics other than for medical or veterinary purposes
Class 5
Pharmaceutical and veterinary preparations for use in the treatment of cystic fibrosispsychosomatic diseasesdepressionepilepsyendocrinologic disorderscirrhosesdiseases associated with hormonal disturbancesautoimmune diseaseseye diseasesobesitymetabolic diseasesstrokeinfectious diseasescancerdegenerative diseasesneurodegenerative diseasesasthmatic diseasesdermatologic diseasesmusculoskeletal diseasesperiodontosisdental diseasesdiabetescardiovascular diseasesinflammatory diseaseshematologic diseasesurologic diseases or erectile dysfunctionspsychological diseasesbroncholytic diseasespulmonary diseasesdermatological diseaseslipid metabolism disordersmigrainedementiarheumatic disordersgastric and intestinal diseasesenzyme deficiency and transport proteins disordersanaleptic diseasesanoretic diseasesblood diseasesallergic diseasesanemic diseasesgeriatric diseasescold and fluhepatic diseasesimmunological diseasescardiac diseasesskeletal and muscle diseasesosteoporosisontological diseasesmouth and pharyngeal diseasesasthmatic diseasesbile-duct disordersarteriosclerosis; medical therapeutic agents for use in the treatment of cystic fibrosispsychosomatic diseasesdepressionepilepsyendocrinologic disorderscirrhosesdiseases associated with hormonal disturbancesautoimmune diseaseseye diseasesobesitymetabolic diseasesstrokeinfectious diseasescancerdegenerative diseasesneurodegenerative diseasesasthmatic diseasesdermatologic diseasesmusculoskeletal diseasesperiodontosisdental diseasesdiabetescardiovascular diseasesinflammatory diseaseshematologic diseasesurologic diseases or erectile dysfunctionspsychological diseasesbroncholytic diseasespulmonary diseasesdermatological diseaseslipid metabolism disordersmigrainedementiarheumatic disordersgastric and intestinal diseasesenzyme deficiency and transport proteins disordersanaleptic diseasesanoretic diseasesblood diseasesallergic diseasesanemic diseasesgeriatric diseasescold and fluhepatic diseasesimmunological diseasescardiac diseasesskeletal and muscle diseasesosteoporosisontological diseasesmouth and pharyngeal diseasesasthmatic diseasesbile-duct disordersarteriosclerosis; biochemical therapeutic agents for use in the treatment of cystic fibrosispsychosomatic diseasesdepressionepilepsyendocrinologic disorderscirrhosesdiseases associated with hormonal disturbancesautoimmune diseaseseye diseasesobesitymetabolic diseasesstrokeinfectious diseasescancerdegenerative diseasesneurodegenerative diseasesasthmatic diseasesdermatologic diseasesmusculoskeletal diseasesperiodontosisdental diseasesdiabetescardiovascular diseasesinflammatory diseaseshematologic diseasesurologic diseases or erectile dysfunctionspsychological diseasesbroncholytic diseasespulmonary diseasesdermatological diseaseslipid metabolism disordersmigrainedementiarheumatic disordersgastric and intestinal diseasesenzyme deficiency and transport proteins disordersanaleptic diseasesanoretic diseasesblood diseasesallergic diseasesanemic diseasesgeriatric diseasescold and fluhepatic diseasesimmunological diseasescardiac diseasesskeletal and muscle diseasesosteoporosisontological diseasesmouth and pharyngeal diseasesasthmatic diseasesbile-duct disordersarteriosclerosisexcept preparations containing theophylline; diagnostic and analytical preparations for medical and veterinary use; biological and chemical diagnostic reagents for medical use
Class 42
Scientific and industrial research in particular in the biologicalbiochemicaldiagnostic and pharmaceutical fields; biochemistry and pharmaceutical laboratory services; scientific and technological servicesscientific researchanalysistestingin particular in the biologicalbiochemicaldiagnostic and pharmaceutical fields; industrial research and analysisservices in development of biologicalbiochemicalpharmaceutical and diagnostic products; research for the identification and further development of biologicalbiochemicalpharmaceutical and diagnostic products
Publications
History of USPTO decisions and trademark events.
45 publications found
71AG
REGISTERED-SEC.71 ACCEPTED
02/02/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
01/26/2026
ES71
TEAS SECTION 71 RECEIVED
09/14/2025
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
10/28/2024
RNWL
INTERNATIONAL REGISTRATION RENEWED
05/24/2024
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
04/30/2023
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
03/09/2023
INPC
INVALIDATION PROCESSED
03/09/2023
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
01/17/2023
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
05/17/2022
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
05/17/2022
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/10/2022
ES71
TEAS SECTION 71 RECEIVED
10/26/2021
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
10/27/2020
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/15/2016
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/12/2016
FIMP
FINAL DISPOSITION PROCESSED
05/12/2016
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/27/2016
R.PR
REGISTERED-PRINCIPAL REGISTER
10/27/2015
GPNX
NOTIFICATION PROCESSED BY IB
08/21/2015
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/11/2015
PUBO
PUBLISHED FOR OPPOSITION
08/11/2015
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/05/2015
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
08/05/2015
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/22/2015
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
07/08/2015
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/07/2015
XAEC
EXAMINER'S AMENDMENT ENTERED
07/06/2015
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/06/2015
GNEA
EXAMINERS AMENDMENT E-MAILED
07/06/2015
CNEA
EXAMINERS AMENDMENT -WRITTEN
07/06/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/24/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/24/2015
ALIE
ASSIGNED TO LIE
06/17/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/10/2015
RFNT
REFUSAL PROCESSED BY IB
12/27/2014
MAFR
APPLICATION FILING RECEIPT MAILED
12/12/2014
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
12/10/2014
RFRR
REFUSAL PROCESSED BY MPU
12/10/2014
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/09/2014
CNRT
NON-FINAL ACTION WRITTEN
12/08/2014
DOCK
ASSIGNED TO EXAMINER
12/08/2014
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/08/2014
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/04/2014
Continuous trademark protection
Get notified about every new filing that threatens AFFILIN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.